Document Detail

High dose of erythropoietin in management of interferon/ribavirin induced anemia.
MedLine Citation:
PMID:  18265628     Owner:  NLM     Status:  MEDLINE    
Accumulating evidence now supports the use of recombinant human erythropoietin (rHuEPO) to manage anemia in PEG-IFN/RBV treated patients, with the objective of maintaining the RBV dose, but currently no official guidelines exist. Actually, rHuEPO exact utilizable dose in PEG-IFN/RBV treated patients is not known. We describe the case of a patient with severe ribavirin-induced anemia.
Claudio Ucciferri; Katia Falasca; Paola Mancino; Domenico De Tullio; Eligio Pizzigallo; Jacopo Vecchiet
Related Documents :
2926928 - Cyanocobalamin injections for patients without documented deficiency. reasons for admin...
3463368 - Decreased bone marrow iron in chronic granulocytic leukaemia: a consistent finding not ...
8237278 - Retrospective study on the influence of human parvovirus b19 infection among children w...
90918 - Iron absorption and loading in beta-thalassaemia intermedia.
6461508 - Contact dermatitis to chlorhexidine.
23530728 - Transepidermal water loss in erythrodermic patients of various aetiologies.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Hepato-gastroenterology     Volume:  54     ISSN:  0172-6390     ISO Abbreviation:  Hepatogastroenterology     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2008-02-12     Completed Date:  2008-03-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8007849     Medline TA:  Hepatogastroenterology     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  2181-3     Citation Subset:  IM    
Clinic of Infectious Diseases, Department of Medicine and Aging University "G d'Annunzio" Chieti-Pescara, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alanine Transaminase / blood
Anemia / drug therapy*
Antiviral Agents / adverse effects*,  therapeutic use
Aspartate Aminotransferases / blood
Erythropoietin, Recombinant / administration & dosage*
Hemoglobins / analysis
Hepatitis C / drug therapy
Middle Aged
Ribavirin / adverse effects*,  therapeutic use
Reg. No./Substance:
0/Antiviral Agents; 0/Erythropoietin, Recombinant; 0/Hemoglobins; 0/epoetin beta; 36791-04-5/Ribavirin; EC Aminotransferases; EC Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nestin expression in neoplastic, fetal, and adult pancreatic endocrine cells.
Next Document:  Can we do better than 'incidental' gallbladder cancer?